Justin Klein, MD, JD
Justin is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner at NEA, where he was a leader of the firm's medical technology investing practice.Full Bio Read Less
Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital. Justin was previously a partner and leader of the medical technology investing practice at NEA, one of the largest and most active venture capital firms in the world. Justin also worked at the Duke University Health System where his experience included roles in strategy, finance and operations as Duke built one of the nation’s first integrated healthcare delivery systems. Justin currently or previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), Epix Therapeutics (acquired), FIRE1, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS. Justin graduated with an AB in Economics, a BS in Biological Anthropology & Anatomy, and a Minor in Chemistry from Duke University. He also concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School.
Kirk Nielsen is a Managing Partner at Vensana Capital. Kirk co-founded Vensana as a Managing Director at Versant Ventures, where he led the firm's medtech practice.Full Bio Read Less
Kirk Nielsen is a Managing Partner at Vensana Capital. Kirk co-founded Vensana as a Managing Director at Versant Ventures, where he led the firm's medtech practice. He joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk led or co-led investments in numerous companies that have successfully exited, including Biotie Therapies, Cameron Health, CardiAQ, Ceterix Orthopaedics, Lutonix, NeuWave Medical, and Sequent Medical, and he remains active with Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical. Kirk graduated with a BA in Biology from Harvard College, where he won the John P. Reardon award as the school's top scholar-athlete, and he earned an MBA from Harvard Business School, where he was a Baker Scholar.
Cynthia Yee is a Principal at Vensana Capital. Cynthia brings over a decade of investing, operating, and equity research experience to Vensana.Full Bio Read Less
Cynthia Yee is a Principal at Vensana Capital. Cynthia brings over a decade of investing, operating, and public equities experience to Vensana. Prior to joining Vensana, she served as a Principal at Windham Venture Partners, where she led the firm’s investments in Cartiva Medical (acquired), ClarVista Medical (acquired), and NeuSpera Medical, and was previously an Associate at NEA focused on investments in medical devices and healthcare services. She also gained operating experience as Director of Business Development & Strategic Marketing at Epix Therapeutics (fka Advanced Cardiac Therapeutics, acquired) and medtech incubator D3DC. Cynthia began her career in public equities, covering medical devices at Piper Jaffray and biotechnology at Pacific Growth Equities. She graduated with a BA in Integrative Biology and a BS in Business Administration at the Haas School of Business at the University of California, Berkeley.
Greg Banker is a Senior Associate at Vensana Capital. Greg has deep experience in the medtech sector gained through operating and strategy consulting roles.Full Bio Read Less
Greg Banker is a Senior Associate at Vensana Capital. Prior to joining Vensana, Greg served as Director of Strategic Market Development at Vertiflex, an interventional spine medical device company that was acquired by Boston Scientific in 2019. Greg's prior experience includes his work as an Associate Director at Navigant Consulting, where he advised medtech CEOs and boards of directors on over two dozen strategic market assessments across a range of sectors including cardiology, interventional pain, orthopedics, neurology, and robotic surgery. He graduated with a BS in Biology from the University of Wisconsin - Madison.